Avenue Therapeutics has announced the filing of a prospectus related to the resale of 1,420,741 shares of common stock by selling stockholders. The shares are comprised of those issuable upon the exercise of Series C and Series D Warrants, as well as Placement Agent Warrants, which were initially issued in a private placement transaction that closed on May 1, 2024. The Series C and D Warrants have an exercise price of $6.20 per share, while the Placement Agent Warrants have an exercise price of $7.75 per share. The Series C Warrants and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, whereas the Series D Warrants are exercisable for eighteen months from issuance. The selling stockholders...Show More

Avenue Therapeutics has announced the filing of a prospectus related to the resale of 1,420,741 shares of common stock by selling stockholders. The shares are comprised of those issuable upon the exercise of Series C and Series D Warrants, as well as Placement Agent Warrants, which were initially issued in a private placement transaction that closed on May 1, 2024. The Series C and D Warrants have an exercise price of $6.20 per share, while the Placement Agent Warrants have an exercise price of $7.75 per share. The Series C Warrants and Placement Agent Warrants are exercisable immediately and for a period of five years from the date of issuance, whereas the Series D Warrants are exercisable for eighteen months from issuance. The selling stockholders may sell the shares at fixed prices, prevailing market prices, or negotiated prices through various methods including block trades, private transactions, or on the open market. Avenue Therapeutics will not receive any proceeds from the sale of the shares but will receive proceeds from any cash exercise of the warrants. The common stock is listed on The Nasdaq Capital Market under the symbol 'ATXI'. The last reported sale price of Avenue Therapeutics' common stock was $4.15 per share as of May 9, 2024.